AU2019278886B2 - Composition and method of treating cancer associated with EGFR mutation - Google Patents

Composition and method of treating cancer associated with EGFR mutation Download PDF

Info

Publication number
AU2019278886B2
AU2019278886B2 AU2019278886A AU2019278886A AU2019278886B2 AU 2019278886 B2 AU2019278886 B2 AU 2019278886B2 AU 2019278886 A AU2019278886 A AU 2019278886A AU 2019278886 A AU2019278886 A AU 2019278886A AU 2019278886 B2 AU2019278886 B2 AU 2019278886B2
Authority
AU
Australia
Prior art keywords
plinabulin
group
pharmaceutically acceptable
acceptable salt
osimertinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019278886A
Other languages
English (en)
Other versions
AU2019278886A1 (en
Inventor
Lan Huang
George Kenneth Lloyd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeyondSpring Pharmaceuticals Inc
Original Assignee
BeyondSpring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeyondSpring Pharmaceuticals Inc filed Critical BeyondSpring Pharmaceuticals Inc
Publication of AU2019278886A1 publication Critical patent/AU2019278886A1/en
Application granted granted Critical
Publication of AU2019278886B2 publication Critical patent/AU2019278886B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2019278886A 2018-06-01 2019-05-30 Composition and method of treating cancer associated with EGFR mutation Active AU2019278886B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862679619P 2018-06-01 2018-06-01
US62/679,619 2018-06-01
PCT/US2019/034726 WO2019232257A1 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with egfr mutation

Publications (2)

Publication Number Publication Date
AU2019278886A1 AU2019278886A1 (en) 2020-12-24
AU2019278886B2 true AU2019278886B2 (en) 2025-03-20

Family

ID=68696755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019278886A Active AU2019278886B2 (en) 2018-06-01 2019-05-30 Composition and method of treating cancer associated with EGFR mutation

Country Status (11)

Country Link
US (2) US20210161888A1 (https=)
EP (1) EP3801524B1 (https=)
JP (1) JP7500438B2 (https=)
KR (1) KR102790127B1 (https=)
CN (1) CN112543636B (https=)
AU (1) AU2019278886B2 (https=)
CA (1) CA3101612A1 (https=)
DK (1) DK3801524T3 (https=)
ES (1) ES3060133T3 (https=)
MX (1) MX420412B (https=)
WO (1) WO2019232257A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383691B (es) 2015-03-06 2025-03-14 Beyondspring Pharmaceuticals Inc Método de tratamiento de cáncer asociado con una mutación de ras.
US10155748B2 (en) 2015-07-13 2018-12-18 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
WO2017139231A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
RU2760348C2 (ru) 2016-06-06 2021-11-24 Бейондспринг Фармасьютикалс, Инк. Способ уменьшения нейтропении
JP2020503363A (ja) 2017-01-06 2020-01-30 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド チューブリン結合化合物およびその治療的使用
BR112019015974A2 (pt) 2017-02-01 2020-03-31 Beyondspring Pharmaceuticals, Inc. Método para reduzir neutropenia
KR20200112881A (ko) 2018-01-24 2020-10-05 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린의 투여를 통해 혈소판감소증을 감소시키는 조성물 및 방법
CA3215047A1 (en) 2021-04-09 2022-10-13 Lan Huang Therapeutic compositions and methods for treating tumors
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
AU2022357570A1 (en) * 2021-10-03 2024-04-11 Systimmune, Inc. Methods of treating cancer and the pharmaceutical compositions thereof
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
EP4719416A1 (en) * 2023-06-02 2026-04-08 Beyondspring Pharmaceuticals, Inc. Oncology combination therapy and methods of use
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054498A2 (en) * 2002-08-02 2004-07-01 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2011034954A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. Treatment of cancer
WO2014130657A1 (en) * 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2016130839A1 (en) * 2015-02-12 2016-08-18 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
WO2016144635A1 (en) * 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation
WO2018169887A1 (en) * 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004054498A2 (en) * 2002-08-02 2004-07-01 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
WO2011034954A1 (en) * 2009-09-15 2011-03-24 Cerulean Pharma Inc. Treatment of cancer
WO2014130657A1 (en) * 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
WO2016130839A1 (en) * 2015-02-12 2016-08-18 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
WO2016144635A1 (en) * 2015-03-06 2016-09-15 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a ras mutation
WO2018169887A1 (en) * 2017-03-13 2018-09-20 Beyondspring Pharmaceuticals, Inc. Compositions of plinabulin and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer", CLINICALTRIALS.GOV, ID: NCT02846792, Record History, Version 5 dated 29 August 2017 *
Mohanlal, R.W. et al., "Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC", Journal of Clinical Oncology, 2017, vol. 35, no. 7, Supplement 1, Abstract 139, DOI: 10.1200/JCO.2017.35.7_suppl.139 *
Remon, J. et al., "Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients", Annals of Oncology, January 2018, vol, 29, Supplement 1, pages i20-i27, DOI: 10.1093/annonc/mdx704 *

Also Published As

Publication number Publication date
DK3801524T3 (da) 2026-02-02
US20250375440A1 (en) 2025-12-11
US20210161888A1 (en) 2021-06-03
KR102790127B1 (ko) 2025-04-03
JP2021525768A (ja) 2021-09-27
CN112543636B (zh) 2024-03-01
EP3801524A1 (en) 2021-04-14
MX420412B (es) 2025-02-10
JP7500438B2 (ja) 2024-06-17
CA3101612A1 (en) 2019-12-05
CN112543636A (zh) 2021-03-23
EP3801524B1 (en) 2025-11-05
KR20210015875A (ko) 2021-02-10
AU2019278886A1 (en) 2020-12-24
WO2019232257A1 (en) 2019-12-05
MX2020012799A (es) 2021-03-25
ES3060133T3 (en) 2026-03-25
EP3801524A4 (en) 2022-03-02

Similar Documents

Publication Publication Date Title
AU2019278886B2 (en) Composition and method of treating cancer associated with EGFR mutation
US20160129003A1 (en) Pharmaceutical Combinations
EP2925366B1 (en) Pharmaceutical combinations
CN105764510A (zh) H3受体拮抗剂与胆碱酶抑制剂组合用于阿尔茨海默氏病治疗中的用途
US20220031657A1 (en) Pharmaceutical combination comprising lsz102 and ribociclib
JP2025509278A (ja) 小細胞肺癌を治療する方法
KR20210084442A (ko) 포도막 흑색종 치료를 위한 병용 요법
EP4203963A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
HK40038993A (en) Composition and method of treating cancer associated with egfr mutation
US20240307392A1 (en) Erk1/2 and egfr inhibitors combination therapy
KR102739607B1 (ko) 카바메이트 화합물을 포함하는 조현병의 예방, 경감 또는 치료용 배합물
CN115120596A (zh) 一种喹唑啉化合物及药物组合物的应用
CN115120732A (zh) 一种喹唑啉化合物的药物组合物及其制备方法
JP2009108058A (ja) 抗リンパ腫組成物および方法
HK1215789B (en) Pharmaceutical combinations

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)